Teriflunomide reduces relapse-related neurological sequelae, hospitalizations and steroid use

Multiple sclerosis (MS) relapses impose a substantial clinical and economic burden. Teriflunomide is a new oral disease-modifying therapy approved for the treatment of relapsing MS. We evaluated the effects of teriflunomide treatment on relapse-related neurological sequelae and healthcare resource u...

Descripción completa

Detalles Bibliográficos
Autores principales: O’Connor, Paul W., Lublin, Fred D., Wolinsky, Jerry S., Confavreux, Christian, Comi, Giancarlo, Freedman, Mark S., Olsson, Tomas P., Miller, Aaron E., Dive-Pouletty, Catherine, Bégo-Le-Bagousse, Gaëlle, Kappos, Ludwig
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2013
Materias:
Original Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3824843/
https://www.ncbi.nlm.nih.gov/pubmed/23852658
http://dx.doi.org/10.1007/s00415-013-6979-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3824843/
https://www.ncbi.nlm.nih.gov/pubmed/23852658
http://dx.doi.org/10.1007/s00415-013-6979-y

Ejemplares similares